Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.69 |
| ▸ | KIT | P10721 | 12/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.64 |
| ▸ | BCR | P11274 | 8/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | LYN | P07948 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | DDX3X | O00571 | 1/20 | 0.59 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551587 | 1.00 | ABL1 (0.69) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL24251038 | 0.95 | ABL1 (0.71) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL29551840 | 0.95 | ABL1 (0.71) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL29551434 | 0.92 | ABL1 (0.69) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL24251098 | 0.92 | ABL1 (0.69) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL24251034 | 0.91 | ABL1 (0.64) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL29551250 | 0.91 | ABL1 (0.64) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL24250969 | 0.91 | ABL1 (0.63) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL29551576 | 0.91 | ABL1 (0.63) | ABL1KITPDGFRBPDGFRABCR | |
| SCHEMBL24250900 | 0.91 | PDGFRA (0.61) | ABL1KITPDGFRBPDGFRABCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | ABL1 695/4885KIT 2333/4885PDGFRB 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.